CD38 and acute graft versus host disease: We present in this study, a collective scientific rationale to support TNB-738, an anti-CD38 enzyme inhibitor antibody, as prophylaxis and/or treatment of inflammatory diseases, such as acute GvHD in patients undergoing allogeneic bone marrow transplantations.